Europe Epigenetics Industry

Europe Epigenetics Market Analysis

The Europe Epigenetics Market is expected to register a CAGR of 14.5% during the forecast period.

The epigenetics market is increasing in the European region. For instance, according to WHO, more than 3.7 million new cases of cancer and 1.9 million deaths occur due to cancer every year, and cancer represents the second most important cause of death and morbidity in the European region. Epigenetics is used in the study of changes in gene expression, which are useful in cancer diagnosis. This depicts the large pool of cancer patients, which will propel the growth of the epigenetics market. So, with the increasing cancer prevalence, the market is expected to grow. However, factors, such as the rising cost of instruments are expected to restrain the growth of the market.

Europe Epigenetics Market Trends

Oncology is Expected to Grow Faster in the Application Segment

In the last few years, the market has been a golden age for cancer genetics. The cost of gene sequencing has dropped low enough for researchers to read the genomes of many thousands of patients, comparing the DNA of the diseased and healthy tissues to find the mutations associated with tumor formation and growth, which is associated with cancer. The epigenetic innovations are unobtrusively crafting a toolbox for the powerful drugs to treat cancer. And the rising prevalence of cancer in the European region is expected to drive the oncology application in the European epigenetic market.

Europe Epigenetics Industry Overview

The European epigenetic market is moderately competitive and consists of several major players. In terms of market share, a few of the major players currently dominate the market. . Some of the major players of the market are Merck & Co., Qiagen, Roche, Thermo Fisher Scientific, and Illumina Inc., among others.

Europe Epigenetics Market Leaders